Literature DB >> 18825391

[Quality assurance and guidelines in rehabilitation for musculoskeletal diseases].

M Glattacker1, E Müller, W H Jäckel.   

Abstract

Diseases of the musculoskeletal system are among the most common and most costly diseases in Germany. They are also associated with a considerable burden for those affected. As a result these disorders also dominate the utilization statistics with respect to medical rehabilitation measures paid for by the statutory pension insurance. In the last 10 years, quality assurance programs have been developed for rehabilitation--initiated and financed by the rehabilitation sponsors--that are characterized by a comprehensive, perspective, pronounced scientific basis, region-wide implementation, and strong patient orientation. The development of guidelines for rehabilitation began later than for acute medicine. In addition to the formulation of guidelines for rehabilitation by medical organizations and professional associations, the German pension insurance has developed so-called process guidelines containing framework requirements for the treatment of defined indication groups rather than support for decision-making in the rehabilitation of individual patients. By planned control of adherence to the process guidelines in the quality assurance programs of the pension insurers prompt implementation of the guidelines can be anticipated.

Entities:  

Mesh:

Year:  2008        PMID: 18825391     DOI: 10.1007/s00393-008-0321-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  17 in total

1.  [Guidelines and evidence-based medicine in Germany].

Authors:  G Ollenschläger; C Thomeczek; H Kirchner; U Oesingmann; F W Kolkmann
Journal:  Z Gerontol Geriatr       Date:  2000-04       Impact factor: 1.281

2.  [Guidelines in medical rehabilitation].

Authors:  W H Jäckel; C Korsukéwitz
Journal:  Rehabilitation (Stuttg)       Date:  2003-04       Impact factor: 1.113

3.  [Rehabilitation guidelines as tool of quality assurance in rehabilitation].

Authors:  Here Klosterhuis
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2005-02

4.  [Quality Assurance in Rehabilitation under the German Pension Insurance Scheme].

Authors:  U Egner; H Gerwinn; R Buschmann-Steinhage
Journal:  Rehabilitation (Stuttg)       Date:  2006-08       Impact factor: 1.113

5.  [Development and psychometric testing of a patient questionnaire for medical rehabilitation (IRES-3)].

Authors:  B Bührlen; N Gerdes; W H Jäckel
Journal:  Rehabilitation (Stuttg)       Date:  2005-04       Impact factor: 1.113

6.  [Quality assurance by patient surveys in medical rehabilitation: assessment and evaluation of rehabilitation structures and processes ("satisfaction of rehabilitation patients")].

Authors:  H Raspe; U Weber; S Voigt; A Kosinski; H Petras
Journal:  Rehabilitation (Stuttg)       Date:  1997-08       Impact factor: 1.113

7.  [Peer review: a method for the analysis of the quality of processing in-patient rehabilitation methods].

Authors:  W H Jäckel; B Maier-Riehle; W Protz; N Gerdes
Journal:  Rehabilitation (Stuttg)       Date:  1997-11       Impact factor: 1.113

8.  [II. Validity and sensitivity to change of the Musculoskeletal Functional Assessment Questionnaire in primary gonarthrosis and total endoprosthetic joint replacement].

Authors:  A König; M Walther; M Matzer; T Heesen; S Kirschner; H Faller
Journal:  Z Orthop Ihre Grenzgeb       Date:  2000 Jul-Aug

9.  [Quality assurance in rehabilitation: where do we stand today?].

Authors:  W H Jäckel; E Farin
Journal:  Rehabilitation (Stuttg)       Date:  2004-10       Impact factor: 1.113

10.  [Quality assurance in outpatient medical rehabilitation - concept and results of a pilot project to develop a quality assurance programme for musculoskeletal and cardiac diseases].

Authors:  E Farin; A Dudeck; C Meffert; M Glattacker; W H Jäckel; U Beckmann; L Böwering
Journal:  Rehabilitation (Stuttg)       Date:  2007-08       Impact factor: 1.113

View more
  1 in total

1.  [Rheumatological rehabilitation today. Exemplified by two case reports].

Authors:  I Ehlebracht-König; W Mau
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.